177 related articles for article (PubMed ID: 36597217)
1. Addition of ruxolitinib in Graft-versus-Host disease prophylaxis for pediatric β-Thalassemia major patients after allogeneic stem cell transplantation: A retrospective cohort study.
Hong X; Chen Y; Lu J; Lu Q
Pediatr Transplant; 2023 Mar; 27(2):e14466. PubMed ID: 36597217
[TBL] [Abstract][Full Text] [Related]
2. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
3. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
4. [The Clinical Observation with Ruxolitinib as Graft-Versus-Host Disease Prophylaxis for Children with Thalassemia after Unrelated or Haploidentical Allo-Hematopoietic Stem Cell Transplantation].
Chen YM; Hong XL; Lin JZ; Shi J; Lu QY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1586-1589. PubMed ID: 36208270
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.
Lebon D; Dujardin A; Caulier A; Joris M; Charbonnier A; Gruson B; Quint M; Castelain S; François C; Lacassagne MN; Guillaume N; Marolleau JP; Morel P
Leuk Res; 2023 Feb; 125():107005. PubMed ID: 36580876
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
[TBL] [Abstract][Full Text] [Related]
7. Comparison of tacrolimus vs. cyclosporine in pediatric hematopoietic stem cell transplantation for thalassemia.
Zhumatayev S; Yalcin K; Celen SS; Karaman I; Daloglu H; Ozturkmen S; Uygun V; Karasu G; Yesilipek A
Pediatr Transplant; 2024 Feb; 28(1):e14688. PubMed ID: 38317344
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
Khandelwal P; Yeh RF; Yu L; Lane A; Dandoy CE; El-Bietar J; Davies SM; Grimley MS
Transplantation; 2021 Apr; 105(4):891-896. PubMed ID: 32467478
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of EB virus infection between short term and long term use of mycophenolate mofetil for prophylaxis of graft versus host disease after haploidentical hematopoietic stem cell transplantation].
Yu CZ; Huang XJ; Xu LP; Liu KY; Zhang XH; Sun YQ; Liu JY; Zhao XY; Wang Y
Zhonghua Nei Ke Za Zhi; 2021 Sep; 60(9):806-811. PubMed ID: 34445816
[No Abstract] [Full Text] [Related]
10. Acute Graft versus Host Disease in Beta Thalassemia Patients Following Allogeneic Haematopoietic Stem Cell Transplantation.
Rafique N; Ali A; Ghaffor T; Khattak TA; Asghar MB; Chaudhry QU
J Coll Physicians Surg Pak; 2024 Apr; 34(4):480-483. PubMed ID: 38576294
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of the efficacies of ruxolitinib plus low-dose PTCY for acute GVHD prevention after haploidentical transplantation in malignant hematological diseases].
Li XP; Li Y; Liu L; Yuan ZT; Wang YC; Dong YC; Zhang DS; Feng J; Chen YN; Wang SB
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):128-133. PubMed ID: 38604788
[No Abstract] [Full Text] [Related]
12. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
[TBL] [Abstract][Full Text] [Related]
13. Goal-Oriented Monitoring of Cyclosporine Is Effective for Graft-versus-Host Disease Prevention after Hematopoietic Stem Cell Transplantation in Sickle Cell Disease and Thalassemia Major.
Gauthier A; Bleyzac N; Garnier N; Kebaili K; Joly P; Goutagny MP; Mollet I; Goutelle S; Renard C; Bertrand Y
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2285-2291. PubMed ID: 32007639
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia.
Zhang B; Chen L; Zhou J; Zu Y; Gui R; Li Z; Wang J; Yu F; Zhang Y; Zhao H; Ji Z; Song Y
Sci Rep; 2021 Apr; 11(1):8501. PubMed ID: 33875780
[TBL] [Abstract][Full Text] [Related]
15. Haploidentical hematopoietic stem cell transplantation for pediatric patients with chronic active Epstein-Barr virus infection: a retrospective analysis of a single center.
Luo YH; Yang J; Wei A; Zhu GH; Wang B; Zhang R; Jia CG; Yan Y; Wang K; Li S; Zhou X; Qin MQ; Wang TY
World J Pediatr; 2021 Dec; 17(6):626-636. PubMed ID: 34739695
[TBL] [Abstract][Full Text] [Related]
16. Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children.
Medina D; Estacio M; Rosales M; Manzi E
Hematol Oncol Stem Cell Ther; 2020 Dec; 13(4):208-213. PubMed ID: 32224144
[TBL] [Abstract][Full Text] [Related]
17. A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis.
Morozova EV; Barabanshikova MV; Moiseev IS; Shakirova AI; Barhatov IM; Ushal IE; Rodionov GG; Moiseev SI; Surkova EA; Lapin SV; Vlasova JJ; Rudakova TA; Darskaya EI; Baykov VV; Alyanski AL; Bondarenko SN; Afanasyev BV
Acta Haematol; 2021; 144(2):158-165. PubMed ID: 32325461
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
[TBL] [Abstract][Full Text] [Related]
19. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
[TBL] [Abstract][Full Text] [Related]
20. Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.
Wang H; Zhao Y; Fang S; Wang L; Peng B; Yang J; Wang N; Du J; Li F; Jin X; Luan S; Wu X; Dou L; Liu D
Transplant Cell Ther; 2022 Jun; 28(6):332.e1-332.e10. PubMed ID: 35314377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]